10x Genomics (NASDAQ:TXG) Shares Gap Up Following Strong Earnings

10x Genomics (NASDAQ:TXG)’s share price gapped up before the market opened on Friday following a better than expected earnings announcement. The stock had previously closed at $17.51, but opened at $19.24. 10x Genomics shares last traded at $19.2650, with a volume of 943,596 shares.

The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. 10x Genomics had a negative return on equity of 6.99% and a negative net margin of 6.77%.The business had revenue of $166.03 million for the quarter, compared to analysts’ expectations of $160.35 million. During the same quarter in the prior year, the business earned ($0.40) EPS. The firm’s revenue for the quarter was up .6% on a year-over-year basis.

Key Headlines Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Q4 beat — 10x reported ($0.13) EPS vs. consensus ($0.19) and revenue of $166.0M vs. $160.4M expected; management highlighted improvement versus prior year which helped the market move. Article Title
• Positive Sentiment: Collaborations — A UK-backed PharosAI cancer-data project using 10x’s Xenium spatial platform was highlighted by commentators as a potential demand driver and positive long‑term validation for the technology. Article Title
• Neutral Sentiment: 2026 outlook — Management provided 2026 revenue guidance of $600M–$625M (consensus ~$624M); guidance narrows expectations but sits near street estimates, leaving upside limited absent stronger visibility. Article Title
• Neutral Sentiment: Analyst takeaway — TD Cowen kept a Hold rating but raised the price target to $19, signaling cautious optimism but limited near-term valuation upside. Article Title
• Neutral Sentiment: Earnings call/transcript — Management commentary (transcript/highlights) provides more color on product adoption, pricing changes and margin trajectory — useful for assessing whether upside can accelerate. Article Title
• Negative Sentiment: Pricing strategy risk — The company is rolling out a new pricing approach that investors view as an earnings test; uncertainty around adoption and near-term revenue impact could pressure multiples if execution stalls. Article Title
• Neutral Sentiment: Short-interest data appears to show zero/erroneous values in recent filings and is not meaningful for current positioning or days-to-cover metrics. (Data anomaly reported by market feeds.)

Wall Street Analyst Weigh In

Several brokerages have issued reports on TXG. Zacks Research downgraded shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. TD Cowen increased their target price on 10x Genomics from $18.00 to $19.00 and gave the stock a “hold” rating in a research note on Friday. UBS Group lifted their price target on 10x Genomics from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $20.00 price objective (up from $17.00) on shares of 10x Genomics in a report on Monday, December 1st. Finally, Deutsche Bank Aktiengesellschaft set a $17.00 price objective on 10x Genomics and gave the stock a “hold” rating in a research report on Friday. Four equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $17.68.

Insider Buying and Selling

In other news, insider Benjamin J. Hindson sold 8,283 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $157,377.00. Following the completion of the sale, the insider directly owned 432,605 shares in the company, valued at approximately $8,219,495. This represents a 1.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Serge Saxonov sold 13,261 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $251,959.00. Following the sale, the chief executive officer directly owned 1,021,556 shares in the company, valued at approximately $19,409,564. This trade represents a 1.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 33,432 shares of company stock valued at $635,208 over the last 90 days. 9.39% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On 10x Genomics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Intech Investment Management LLC boosted its position in shares of 10x Genomics by 1.4% during the 4th quarter. Intech Investment Management LLC now owns 40,047 shares of the company’s stock worth $653,000 after acquiring an additional 567 shares in the last quarter. Teacher Retirement System of Texas lifted its stake in 10x Genomics by 6.1% during the second quarter. Teacher Retirement System of Texas now owns 14,931 shares of the company’s stock worth $173,000 after purchasing an additional 858 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of 10x Genomics by 3.0% in the 3rd quarter. Arizona State Retirement System now owns 29,586 shares of the company’s stock valued at $346,000 after purchasing an additional 872 shares in the last quarter. Certuity LLC boosted its holdings in shares of 10x Genomics by 4.7% in the 4th quarter. Certuity LLC now owns 20,204 shares of the company’s stock valued at $330,000 after purchasing an additional 904 shares in the last quarter. Finally, Versant Capital Management Inc increased its stake in shares of 10x Genomics by 3.3% in the 3rd quarter. Versant Capital Management Inc now owns 29,364 shares of the company’s stock valued at $343,000 after purchasing an additional 945 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Performance

The company has a market cap of $2.29 billion, a price-to-earnings ratio of -51.77 and a beta of 2.24. The business has a fifty day moving average price of $18.67 and a 200 day moving average price of $15.60.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.